Therapy Areas: Infectious Diseases
Aptorum Group Develops Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
9 September 2019 - - US-based biopharmaceutical company Aptorum Group Ltd. (NASDAQ: APM) is developing two preclinical drug candidates which target obesity and neuroblastoma, respectively, the company...
Aptorum Group Develops Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
9 September 2019 - - US-based biopharmaceutical company Aptorum Group Ltd. (NASDAQ: APM) is developing two preclinical drug candidates which target obesity and neuroblastoma, respectively, the company...
US FDA grants Breakthrough Therapy designation to Ridgeback Biotherapeutics' Ebola treatment
9 September 2019 - The US Food and Drug Administration (FDA) has granted Ridgeback Biotherapeutics LP, a biotechnology company, Breakthrough Therapy designation for its mAb114, an experimental Ebola t...
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
30 August 2019 - - US-based pharmaceutical company VenatoRx Pharmaceuticals has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (c...
Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children's Hospital Receive a USD 2.3m Dollar Phase II SBIR Grant to Develop Novel Therapy
23 August 2019 - - US-based Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, are a recipient of a Phase II SBIR gra...
VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
22 August 2019 - - US-based VenatoRx Pharmaceuticals has added pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team, the company said.